Can the US Afford to Ignore Cost-Effectiveness Evidence in Health Care?

At this OHE Lunchtime Seminar, Dr James Chambers of Tufts University presented material drawing on his upcoming OHE Research Paper, which looks at the role cost-effectiveness evidence plays in health care resource allocation in the US.  The presentation will cover the potential value of expanding that. Specifically for Medicare, the federal  insurance programme for people 65+, Dr Chambers noted whether its coverage decisions for medicines are consistent with cost-effectiveness evidence.  He also discussed the potential benefits of including economic evidence in Medicare coverage policy in terms of aggregate health gains and cost-savings. Lastly, he discussed the challenges associated with incorporating cost-effectiveness evidence into coverage policy, including implications of the 2010 US health care reform legislation.

James D Chambers, PhD, MSc, MPharm, is an Assistant Professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies at the Tufts University School of Medicine in Boston, Massachusetts. He leads and works on projects associated with the use of cost-effectiveness evidence in the US health care system. Dr Chambers also is involved in maintaining the Tufts Medical Center’s Medicare National Coverage Decisions (NCD) database. His research interests include what factors influence medical technology coverage policy and the role of cost-effectiveness evidence in decision-making.

The slides from Dr Chambers' preserntation are available by clicking here.

Wednesday, 24 July 2013